Allergan, PLC.April 11, 2019

FDA 483 - Allergan, PLC. - April 11, 2019

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Allergan, PLC.

Record Details

An FDA inspection of Allergan, PLC.'s corporate headquarters in Madison, NJ, revealed significant deficiencies in their Risk Evaluation and Mitigation Strategy (REMS) program for opioid analgesics. The firm failed to properly dispense the required Medication Guide and did not adequately maintain its REMS program website and support systems. These issues indicate a failure to ensure critical safety information is accessible to patients and healthcare providers.

Company: Allergan, PLC.
Inspection Date: April 11, 2019
Product Type: Drugs
Office: New Jersey District Office
Person: Michael Serrano (investigator)

Open in Dashboard

ID · ef413229-6a75-4f53-9264-6de0bad68326